Switching to dual therapy (atazanavir/ritonavir+lamivudine) vs. standard triple therapy (atazanavir/ritonavir+2 nucleos[t]ides) is safe and effective in virologically suppressed patients: 48-week results of a randomized clinical trial (SALT study)
Services
Services
Date issued
2014Journal title
Enfermedades Infecciosas y Microbiologia Clinica
Type of content
Publicación de congreso
